curriculum vitae

Harald Hampel
Harald Hampel

Professor Harald Jürgen Hampel, MD, PhD, MA, MSc

LinkedIn    ResearchGate    PubMed    YouTube

AXA Research Fund & UPMC Excellence Chair

Sorbonne Universités Université Pierre et Marie Curie Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A) & Institut du Cerveau et de la Moelle épinière (ICM) Département de Neurologie Hôpital de la Pitié-Salpétrière 75013 Paris, France



1994     M.D., University of Munich, Germany

1996     Ph.D., University of Munich, Germany

2007     M.Sc., University of Cologne (KFH), Germany

2008     M.A., Trinity College, University of Dublin, Ireland


1994     Licence to practise as a physician (approbation)

2002     Licence as Consultant in General Adult Psychiatry and Psychotherapy

2005     Licence as Consultant in Clinical Geriatrics (FW)

2006     Full registration as Medical Specialist in Ireland in General Adult Psychiatry and Psychiatry of Later Life, Medical Council Ireland

2008     Appointment as Professorial Fellow of Trinity College, University of        Dublin, Ireland


1993 – 1995     Resident & Chief Resident, Department of Psychiatry, University of Munich, Germany

1995 – 1997     Postdoctoral Fellow, NIH, NIA, Laboratory of Neurosciences, Bethesda, USA

2001 – 2009     Founding Director, Alzheimer Memorial Center, University of Munich

2005 – 2007     Full Professor of Psychiatry, Department of Psychiatry, University of Munich, Germany

2007 – 2009     Full tenured Professor & Chair of Psychiatry, PI at Trinity College, Institute of Neuroscience, Trinity College, University of Dublin, Ireland

2010 – 2013     Full tenured Professor & Chair of Psychiatry, Head of Department of Psychiatry, Psychosomatic Medicine & Psychotherapy, Head of Laboratory of Neuroscience, Alzheimer Research Center, Co-director of the Brain Imaging Center (BIC), Goethe University, Frankfurt/Main, Germany

2013 – ongoing     Full tenured Professor & AXA Research Fund & UPMC Excellence Chair, Sorbonne Universités, Université Pierre et Marie Curie, Scientific Director of the Institut de la Mémoire et de la Maladie d’Alzheimer & Principal Investigator at the Institut du Cerveau et de la Moelle épinière (ICM), Département de Neurologie, Hôpital de la Salpêtrière, Paris, France 


2007-2011     Visiting Professor         University of Munich, Germany

2009-2011     Adjunct Professor         Trinity College, University of Dublin, Ireland

2013-permanent     Visiting Professor         University of Belgrade, Serbia 

2014-2016     Member of the Academic Committee of the 6th Hospital of Peking University and the City Key Laboratory of Dementia Translational Medicine, Beijing, China


1986 – 1991    Scholarship, Witten-Herdecke University, School of Medicine, Germany

1986 – 1993     Scholarship, German National Academic Foundation Scholarship (c/o Studienstiftung des Deutschen Volkes, Bonn, Germany)

1988     Scholarship, German National Academic Foundation, Columbia University, New York, New York, USA

1990     Scholarship, German National Academic Foundation, International Rotation Program, Lady Willingdon Hospital, Manali, Himachal Pradesh, India

1992      Scholarship, Biomedical Sciences Exchange Program between North America and Europe (BMEP) (c/o The Mount Desert Island Biological Laboratory, Salsbury Cove, Maine, USA), Albert Einstein College of Medicine, Bronx, New York, USA

1995 – 1996     Scholarship, Ernst Jung-Foundation for Science and Research (c/o Hamburg, Germany), associated with the Ernst Jung Medal in Gold (Prof. H. Hippius), National Institutes of Health, Bethesda, Md., USA

1998     Bernhard-von-Gudden Award (endowed with 10.000 €)

2003    German Brain Foundation Research Award (endowed with 12,500 €)

2004    Alois Alzheimer Award (endowed with 10.000 €)

2004    International Human Brain Mapping Society Paper Award

2006    Kraepelin-Alzheimer-Medal

2008    Professorial Fellowship, Trinity College, University of Dublin, Ireland

2010    Katharina-Hardt-Foundation Research Award (endowed with 6.000 €)

2011    Katharina-Hardt-Foundation Research Award (endowed with 15.000 €)


Translational discovery, development and validation of novel treatments (in more than 50 clinical trials) and multimodal biomarker candidates using biochemical (blood, plasma & CSF) and neuroimaging methods in mono- and multi-site studies for risk assessment, mapping progression, prediction, early detection, clinical diagnosis and classification (differential diagnosis) of neurodegenerative diseases (such as Alzheimer’s disease [AD]) across all disease stages (preclinical to prodromal to dementia).

Detection of genetic protection and risk variants (such as several genome-wide associated susceptibility genes) of autosomal dominant and sporadic Alzheimer’s disease within large-scale international research networks.

Neurochemical biomarker work focused on inflammatory markers (such as the TNF receptor complex, the IL-6 receptor complex), total and phosphorylated tau protein (s199, thr181, thr231), abeta-antibodies and abeta-oligomers (correlation with cognitive decline), TACE and BACE1 functional proteins, microvascular markers (in brain, CSF and plasma). Validation of biomarkers against post-mortem histochemical findings (e.g., p-tau thr231 correlation with regional brain tangle density).

Pr Hampel’s group has introduced and systematically validated (from mono-center methodological studies to multi-site validation) various new MR-biomarkers, e.g., of limbic system and basal forebrain changes validated against post-mortem obtained brain scans.

Multivariate analysis tools were developed to track white matter changes, cortical thickness analysis, voxel-based DTI analysis of the whole brain (including large-scale multi-center validation studies), demonstrating a specific AD pattern of fractional anisotropy and identifying anatomical neural networks using advanced tractography within the brain. Voxel- and deformation-based morphometry.

For the functional MRI assessment, he developed a connectivity-related approach that showed brain changes in subjects at risk of AD before the onset of dementia.

Metabolic imaging focused on studies at rest and activation using FDG- and Amyloid-PET tracers. It is planned to expand studies using PET-Tau protein and inflammation ligands. His current neuroimaging research focuses on the understanding how the brain constructs networks of interacting regions to perform cognitive tasks, especially those associated with memory and attention, and how these networks are altered during aging and neurodegenerative brain diseases.


(1) the emergence of the network paradigm, due in large part to neuroimaging; instead of thinking of the brain as a set of modules (i.e., individual brain regions) that perform specific cognitive functions, the network paradigm argues that cognitive functions are performed by dynamic interactions among different brain areas – i.e., by dynamically formed functional networks of brain regions; and

(2) the emergence of neural modeling required by the network paradigm, since to deal with the complexity of the dynamic interactions among multiple brain regions, one must employ computational methods.

(3) the emergence of the systems biology paradigm. Systems biology represents an integrated and deeper investigation of interacting biomolecules within cells or organisms. This approach has only recently become feasible as high-throughput technologies including cDNA microarrays, mass spectrometric analyses of proteins and lipids together with rigorous bioinformatics have evolved. High-content data point to convergent pathways among neurodegenerative diseases, which trans­cend descriptive studies to reach a more integrated un­derstanding of disease pathogenesis and, in some instances, highlighting ‘druggable’ network nodes.


  • Executive Board of the international Consortium for the Establishment of Biomarkers Across Neurodegenerative Diseases (CE-BAND) and Alzheimer Association ISTAART Professional Interest Group (PIA) on Blood-based Biomarkers (BBBI)
  • Scientific director of the Alzheimer and Memory Institute in Paris (Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A)), the leading French Memory Center and Alzheimer & Neurodegeneration Research Institute, National Reference Center for Young onset AD, Rare Neurodegenerative and Dementia Diseases
  • Scientific Coordinator of the internationally pioneering “Institut Hospitalo Universitaire” (IHU) and the industry-funded French flagship research program INSIGHT
  • (INveStIGation of AlzHeimer’s PredicTors in Subjective Memory Complainers)
  • Co-Principal Investigator (Co-PI) and Scientific Coordinator of the SOCRATES program (Structurizing and follow-up of a cohort in routine care concerning highly phenotyped patients with neurodegenerative diseases and Alzheimer’s disease).
  • Scientific Program Committee of the annual Alzheimer Awards (FRA), Paris, France
  • Genetic and Environmental Risk for Alzheimer’s disease (GERAD1) Consortium (Co-PI)
  • Faculty member of the Lundbeck International Neuroscience Foundation (LINF)
  • Senior Associate Editor heading the biomarker branch of the leading scientific journal Alzheimer’s and Dementia of the Alzheimer’s Association (Chicago, Il., USA)
  • Alzheimer Association ISTAART Professional Interest Group (PIA) on Subjective Cognitive Decline (SCD)
  • Scientific Executive Committee member of Jung Diagnostics, Hamburg, Germany
  • Member of the GERARD/PERADES international genetics network
  • Member of Global, European and National Scientific Advisory Boards of international Pharmaceutical, Biotech and Diagnostics companies.


Total number 563

(e.g. 2x New England Journal of Medicine, 4x Nature Genetics, 2x Nature Reviews Drug Discovery,    3x Nature Reviews Neurology, 2x JAMA, The Lancet, 3x Lancet Neurology, etc.):

295 peer-reviewed original research papers, >185 review articles, 75 book chapters, 8 books (editor), >500 abstracts to scientific meetings, >500 invited oral presentations (several invited keynote and plenary lectures at major international meetings).

Hirsch-Factor                         >50


Impact Factor Points          4290.57

RG-Score                               51.46

Citations                             22264

Profile views                        7117

Publication views                 63550

Publication downloads               11730

  • SELECTED ARTICLES                                                         
    1. Steinberg S, Stefansson H, Jonsson T,…, Hampel H,…Snaedal J, Stefansson K. Loss of function variants in ABCA7 confer risk of Alzheimer’s disease. Nature Genetics, accepted. (IF=29.648).
    2. Jansen WJ, Ossenkoppele R,…Hampel H,…Zboch M, Zetterberg H. Prevalence of Cerebral Amyloid Pathology in Persons without Dementia: A Meta-analysis. JAMA – Journal of the American Medical Association. 2015 May 19;313(19):1924-1938. doi: 10.1001/jama.2015.4668. (IF= 30.387).
    3. Ewers M, Mattsson N,…, Blennow, Hampel H. Differential diagnosis of Alzheimer’s disease using cerebrospinal fluid biomarkers. A large-scale international multi-center study. Alzheimer’s and Dementia, 2015 (IF 17.472).
    4. Dubois B, Feldman HH, Jacova C, Hampel H, …, Scheltens P, Cummings JL. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurology. 2014 Jun;13(6):614-29. doi: 10.1016/S1474-4422(14)70090-0. (IF 21.823).
    5. Lautner R, Palmqvist S, …Hampel H, … Zetterberg H, Hansson O; for the Alzheimer’s Disease Neuroimaging Initiative. Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alz-heimer Disease. JAMA Psychiatry, 2014 Aug 27. doi: 10.1001/jamapsychiatry.2014.1060. (IF 13.77).
    6. Aisen P, Vellas B, Hampel H. Moving towards early clinical trials for amyloid‐targeted therapy in Alzheimer’s disease. Nature Reviews Drug Discovery, 2013. (IF 29.008).
    7. Lambert JC, Ibrahim-Verbaas CA,… Hampel H,… Amouyel P. Extended meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nature Genetics, 2013 October 27; doi: 10.1038/ng.2802. (IF 35.532).
    8. Guerreiro R, Wojtas A, …, Hampel H,…Walker R, Weale M. TREM2 variants in Alzheimer’s disease. New England Journal of Medicine, 2013 Jan 10;368(2):117-127. doi: 10.1056/NEJMoa1211851. (IF 53.298).
    9. Hampel H, Lista S. Alzheimer disease: From inherited to sporadic AD-crossing the biomarker bridge. Nature Reviews Neurology, 2012 Nov 5;8(11):598-600. (IF 12.461).
    10. Jonsson T, Stefansson H,…, Hampel H,…,Kong A, Stefansson K. A Coding Variant in TREM2 Confers Risk of Alz heimer’s Disease. New England Journal of Medicine, 2012. DOI: 10.1056/NEJMoa1211103. (IF 53.298).
    11. Hampel H, Lista S, Khachaturian ZS. Development of biomarkers to chart all Alzheimer’s disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimer’s and Dementia, 2012 Jul;8(4):312-336. (IF 14.483).
    12. Ewers M, Sperling RA, Klunk WE, Weiner MW, Hampel H. Neuroimaging markers for the prediction and early diagnosis of Alzheimer’s disease dementia. Trends in Neurosciences. 2011; 34(8):430-42. (IF 13.320)
    13. Frisoni GB, Hampel H, O’Brien JT, Ritchie K, Winblad B. Revised criteria for Alzheimer’s disease: what are the lessons for clinicians? Lancet Neurology. 2011; 10(7):598-601. (IF 21.659)
    14. Hollingworth P, Harold D, … , Hampel H, … Williams J. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nature Genetics. 2011; 43(5):429-35. (IF 36.377
    15. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K. Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives. Nature Reviews in Drug Discovery. 2010; 9(7):560-74. (IF 29.059
    16. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature Reviews Neurology. 2010; 6(3):131-44.
    17. Buschert V, Bokde ALW, Hampel H. Cognitive intervention in Alzheimer’s disease. Nature Reviews Neurology. 2010; 6(9):508-17.
    18. Dubois B, Feldman HH, … , Hampel H, … Scheltens P. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurology. 2010; 9(11):1118-27. (IF 18.126)
    19. Harold D, Abraham R, … Hampel H,…Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nature Genetics. 2009; 41(10):1088-93. (IF 30.259)
    20. Mattsson N, Zetterberg H, … , Hampel H, … Winblad B, Blennow K. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA – Journal of the American Medical Association. 2009; 302(4):385-93. (IF 31.718)
    21. Visser PJ, Verhey F, … , Hampel H, … Blennow K. Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurology. 2009; 8(7):619-27. (IF 14.270)
    22. Gauthier S, Reisberg B, … , Hampel H, … Winblad B. Mild cognitive impairment. The Lancet. 2006; 367(9518):1262-70. (IF 25.800)



Senior Associate Editor of the journal of the US Alzheimer Association Alzheimer’s & Dementia and founding editor and head of the newly established Biomarker Branch (Impact Factor 17.472)

Associate Editor: Journal of Alzheimer’s disease, Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring’ (DADM), European Journal of Neurodegeneration, Brain Aging, Functional Neurology; Editorial Board Member: Neuroscience Imaging, Journal of Medical Psychology, World Journal of Neurology, World Journal of Pharmacology, Journal of Diagnostics, European Journal of Neurodegeneration, Journal of Diagnostic Imaging in Therapy.


New England Journal of Medicine, Nature Medicine, Nature Reviews Drug Discovery, The Lancet, Neuron, JAMA Neurology, JAMA Psychiatry, PNAS, Journal of Neuroscience, Trends in Neuroscience, Progress in Neurobiology, Lancet Neurology, Annals of Neurology, Neurology, Archives of General Psychiatry, Brain, American Journal of Psychiatry, Biological Psychiatry, Molecular Psychiatry, Expert Review of Molecular Diagnostics, etc.


  1. German National Research Foundation (Deutsche Forschungsgemeinschaft (DFG)), Germany (number one medical grant institution in Germany);
  2. German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung (BMBF)), Germany;
  3. Swiss National Foundation for the Advancement of Science (Switzerland’s Nationalfonds            zur Förderung der Wissenschaftlichen Forschung (FNSNF)), Switzerland (number one medical grant institution in Switzerland);
  4. US-Israel Binational Industrial Research and Development (BIRD) Foundation, c/o NIST,            the National Institute of Standards and Technology, Gaithersburg, Maryland, USA
  5. Medical Research Council (MRC), UK
  6. The Wellcome Trust, London, UK
  7. The PPP Foundation, London, UK
  8. Alzheimer’s Society, London, UK
  9. The College of Psychiatry of Ireland
  10. Scottish Executive Health Department, Edinburgh, UK
  11. Alzheimer’s Research Trust, UK
  12. Pacific Alzheimer Research Foundation (PARF), Canada
  13. Weston Brain Institute & Foundation, Toronto, Canada
  14. Alzheimer Research Initiative (Alzheimer Forschung Initiative e.V., AFI), Düsseldorf, Germany
  15. International Alzheimer Association, Chicago, USA
  16. Alzheimer International
  17. Alzheimer Nederland
  18. Research Grants Council (RGC), Hongkong, China
  19. Hungarian Scientific Reseach Fund (OTKA)
  20. Israel Science Foundation’s F.I.R.S.T. (Focal Initiatives in Research in Science & Technology)
  21. CONSOLIDER, CONSOLIDER-Ingenio Programme
  22. French National Research Agency (Agence Nationale de la Recherche, ANR), Paris, France
  23. Tiroler Wissenschaftsfonds, Innsbruck, Austria
  24. Croatian Science Foundation (CSF), Zagreb/Opatija, Croatia
  25. Alzheimer Forschung Initiative e.V. (AFI), Düsseldorf
  26. The Netherlands Organisation for Scientific Research (NWO)
  27. Université Sorbonne Paris Cité (USPC)


During the last 36 months Dr. Hampel has received lecture honoraria and/or research grants and/or travel funding and/or participated in scientific advisory boards and/or as a consultant to diagnostic, biotechnology and pharmaceutical companies involved in the manufacture and marketing of biomarkers and/or diagnostics and/or drugs or medicinal products for cognitive impairment and Alzheimer’s disease including Boehringer-Ingelheim, Bristol-Myers Squibb, Elan Corporation, Novartis, Eisai Inc., Pfizer, Sanofi-Aventis, Roche Pharmaceuticals and Diagnostics, GE Healthcare, Avid, Eli Lilly and Company, GlaxoSmithKline-Biologicals, Jung-Diagnostics, Cytox. Dr. Hampel is co-inventor in (partly pending) patent submissions relating to biological markers and/or diagnostics.


Laisser un commentaire

Entrez vos coordonnées ci-dessous ou cliquez sur une icône pour vous connecter:


Vous commentez à l'aide de votre compte Déconnexion /  Changer )

Photo Google+

Vous commentez à l'aide de votre compte Google+. Déconnexion /  Changer )

Image Twitter

Vous commentez à l'aide de votre compte Twitter. Déconnexion /  Changer )

Photo Facebook

Vous commentez à l'aide de votre compte Facebook. Déconnexion /  Changer )


Connexion à %s